While previous work has demonstrated a role for tamoxifen or fulvestrant in the radiosensitisation of ER+ breast cancer models in vitro and in vivo [22], the role of AR and ER together and the impact on radiosensitisation has not been assessed. The gene discussed is AR; the disease is breast cancer.